# NCT05912244 (NCT05912244)

> A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05912244
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Memorial Sloan Kettering Cancer Center
- Conditions: Melanoma
- Interventions: IO102/IO103; Nivolumab-Relatlimab
- Enrollment: 43
- Primary outcome: Overall Response Rate (ORR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 3
- Podcasts: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05912244